|
JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy—A Spanish Oncologic Genitourinary Group (SOGUG) study. |
|
|
Consulting or Advisory Role - Sanofi |
Research Funding - Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
Speakers' Bureau - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi (Inst) |
|
Aránzazu Gonzalez del Alba |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |
|
|
Consulting or Advisory Role - Sanofi |